Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Therapeutic Advances in T-Cell Lymphoma in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Barta

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Top Risk Factors for Cancer by Sex and What to Do About It

MedCram

R. Seheult

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Epcoritamab in NHL - Incidence and Management of CRS

GRACE

T. Phillips

Update on Cellular Therapy in Lymphoma

Total Health

B. Randolph

Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do a…

Indy Hematology Review

T. Phillips

Novel Combinations in Indolent Lymphoma

SOHO 2023 Eleventh Annual Meeting

P. Strati

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

Monia Marchetti

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

SOHO Brazil 2024

A. Zelenetz

Treatment-Related Quality of Life in MF

Winship Cancer Institute - Emory University

A. Hunter